Roche Holding AG (RHHBY)
| Market Cap | 315.77B +22.1% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 19.44 |
| Forward PE | 15.47 |
| Dividend | 0.97 (1.88%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 1,465,057 |
| Open | 50.44 |
| Previous Close | 51.06 |
| Day's Range | 49.22 - 50.50 |
| 52-Week Range | 37.51 - 60.85 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 56.66 (+13.91%) |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $56.66, which is an increase of 13.91% from the latest price.
News
The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs
The investigation comes after Berlin said it would require drugmakers to offer bigger discounts on medicines.
U.S. opens tariff probe targeting Germany's drug pricing policies
The U.S. said the probe will examine whether "persistent underpayment" for medicines by Germany is discriminatory. "President Trump has made clear that American patients should not be shouldering a di...
Genentech says FDA accepts sBLA for for Lunsumio VELO
Genentech, a member of the Roche (RHHBY) Group, announced that the U.S. FDA has accepted the company’s supplemental Biologics License Application for Lunsumio VELO, as a subcutaneous formulation, in c...
FDA accepts supplemental Biologics License Application for Roche's Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Basel, June 18, 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) fo...
FDA Accepts Supplemental Biologics License Application for Genentech's Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
FDA approves first generic version of Roche's flu drug
The U.S. Food and Drug Administration approved the first generic version of Roche's Xofluza, a single-dose flu medicine for certain patients aged five years and older, the regulator said on Wednesda...
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...
Roche reports FDA approval for prostate cancer companion diagnostic
Roche (RHHBY) announced that the Ventana PTEN RxDx Assay is the first immunohistochemistry companion diagnostic test to receive U.S. Food and Drug Administration approval for determining PTEN protein ...
OraSure announces FDA clearance of Colli-Pee Dx Urine Collection Kit
OraSure (OSUR) announced FDA clearance of its Colli-Pee Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche’s (RHHBY) tests for Chlamydia trachomatis, Neisseria gonorrhoea...
Genentech granted priority review for Tecentriq Hybreza combination
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application, or sBLA, filing for adjuvant Tecentriq and Tecentriq Hybreza in comb...
Roche announces EU IVDR approval of several Ventana label expansions
Roche (RHHBY) announced the European Union In Vitro Diagnostic Regulation, or IVDR, approval of several label expansions for the Ventana MMR RxDx Panel, an immunohistochemistry companion diagnostic te...
FDA Grants Priority Review for Genentech's Tecentriq for a Certain Type of Stage III Colon Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapies By evaluating a panel of MM...
FDA grants Priority Review for Roche's Tecentriq for a certain type of stage III colon cancer
Basel, 11 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) f...
Roche sticks to German investment after Eli Lilly cuts
The Swiss pharmaceutical and diagnostics giant Roche said it is sticking to its planned investments in Germany, unlike some of its competitors that have scaled back spending in the country.
Roche Holding AG Transcript: Study update
Phase II results show enicepatide achieved up to 22.7% weight loss at 48 weeks, with strong glycemic improvements and favorable tolerability. Petrelintide demonstrated up to 10.7% weight loss with a placebo-like safety profile, supporting its use for moderate weight loss. Both agents advance to phase III, with combination studies planned.
Roche Holding AG Slides: Study update
Roche Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.
Nurix Therapeutics Stock (NRIX) Soars 40% After $2.3B Blood Cancer Deal with Roche
Shares in biopharmaceutical company Nurix Therapeutics ($NRIX) soared nearly 40% in pre-market trading after sealing a $2.3 billion blood cancer deal with Swiss pharmaceutical giant Roche ($RHHBY). Bl...
Nurix Therapeutics teams with Roche to develop, commercialize bexobrutideg
Nurix Therapeutics (NRIX) announced a global collaboration with Roche (RHHBY) to develop and commercialize bexobrutideg, an oral degrader of Bruton’s tyrosine kinase, or BTK. The partnership brings to...
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday.
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clini...
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche's oncology pipeline and offers potential indica...
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity drug, with more than a quarter of those who received the highest dose a...